15 April 2013Americas

Supreme Court to hear oral arguments in Myriad case

Myriad Genetics will deliver an oral argument at the US Supreme Court today (Monday, April 15) defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent